Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028 Report Highlights:
- Global Nanoparticle Drug Delivery Market Opportunity > USD 300 Billion by 2028
- Nanoparticle Drug Delivery Price & Dosage Insight By Therapeutic (Cancer, Anemia, Autoimmune Diseases, Neurological Disorders)
- Nanoparticle Therapeutics Approved Drugs Sales Analysis & Forecast Till 2028
- Global Nanoparticle Drugs Clinical Pipeline Insight By Phase, Company & Indication
- Nanoparticle Drug Delivery – Market Trend & Patent Distribution Analysis
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646380145
Currently the most common route of administration of therapeutics is topical, oral, intravenous, epidermal and intradermal with nasal, vaginal and colorectal routes being less common. The delivery of drugs from the sight it was administered to the site it is supposed to reach can drastically decrease the overall efficacy and therapeutic efficacy. Fortunately, with the advancement in science and technology and the emergence of cutting edge technology, the drug delivery segment has had a groundbreaking impact in modern drug delivery techniques. Amongst multiple drug deliver techniques that are currently under rapid development, nanoparticles clearly stands out to be the leading drug delivery method.
Nanoparticles (NP) are a type of colloidal drug delivery system comprising particles with a size range from 10 to 1000 nm in diameter. The idea behind making use of specially designed nanoparticles is to administer the active ingredient of a particular therapeutic compound accurately to the target side without wasting it. Further, these nanoparticles are capable of delivering just the right amount of dosage to the site, thus preventing any form of overdose. Over the years, pharmaceutical companies have developed several potent nanoparticle based drugs which have demonstrated much better efficacy and safety than traditional drugs.
The nanomedicines which have been approved have been indicated for the management of wide range of diseases including cancer, central nervous system (CNS) diseases, cardiovascular disease, infection control, and others. Apart from this, the novel approach has also raised hope in complex diseases like brain tumor, which is currently impossible to treat with conventional drug delivery methods. The entrance of nanoparticle drug delivery has shown tremendous growth rates from last few years and is expected to dominate the drug delivery market during forthcoming years. The huge investments by pharmaceutical giants in this segment has led to development of several clinical candidates including including Promitil, ThermoDox, Oncoprex, EP0057, Nanocort, NLG-207, Liposomal Kanamycin, and others. These are expected to enter the market in coming years which will drive the growth of market during the forecast period.
Apart from oral drugs, researchers have also expanded the idea of nanotechnology towards vaccine development. So far, two nanoparticle formulated, mRNA based COVID-19 vaccines have been developed, clinically tested and marketed during the ongoing pandemic. These vaccines are BNT162b2 by Pfizer/BioNTech and mRNA-1273 by Moderna. Apart from this, two vaccines are present under development such as NVX-CoV2373 vaccine (Novavax).
Further to mitigate the high cost associated with nanoparticle drugs, the research is mainly focused on the development of cost-effective generic drugs. The generic nanoparticle drug has also seen substantial rise in production as they are less expensive than branded and do not require extensive research and testing. Several pharmaceutical companies including Mylan, Teva, Actavis, Lupin Laboratories, Sun Pharma, and others have launched their generic versions in the market, which have shown high acceptance.
As per our report findings, the global nanoparticle drug delivery market is expected to surpass US$ 300 Billion by 2028. The high incidence of cancer and other chronic disorders, increasing investments in pharmaceutical research and development, contract development, and manufacturing organizations (CDM0) investing in advanced technologies, and increasing partnerships and agreements between pharmaceutical companies and CDMO will drive the market growth. The major companies mentioned in the report include Abbvie, Amgen, Pfizer, Tandem Nano, Horizon Therapeutics, Biogen, Bristol Myers Squibb, Nanobiotix, and others. Furthermore, more than 500 clinical trials are ongoing globally which are evaluating novel nanomedicine drug delivery in wide range of therapeutic indications. The coming years is expected to witness rapid approval of the drugs in the market which will further boost the growth of market during the forecast period.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366